Previous 10 | Next 10 |
Precipio (PRPO): FY Gross profit of $0.5MRevenue of $1.9M (+171.4% Y/Y)Shares +4.48%.Press Release For further details see: Precipio reports FY results
NEW HAVEN, Conn., March 30, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics Company Precipio, Inc. (NASDAQ: PRPO) , announced its audited results for 2020. The Company posted revenues of $6.1 million, an increase of $3.0 million from 2019, representing a 95% year-over-year in...
NEW HAVEN, Conn., March 18, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q4-2020 and year end corporate update call on Wednesday, March 31 st at 5:00 PM ET. The call will include updates on all of the company...
NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that Mr. Ron Andrews has joined the company’s Board of Directors. As the company continues to build its products division around comme...
Precipio ([[PRPO]] +1.6%) appoints Richard Sandberg as its board chairman, succeeding Douglas Fisher who will continue in the role of director.Sandberg has been involved with Precipio since its inception and joined its board in 2019, contributing through strategy form...
NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his rol...
Are Biotech Penny Stocks Part Of Your Strategy In 2021? It’s February 2021, and the markets are at all-time highs. Trading volumes remain strong, and penny stocks continue captivating retail traders. We also see several hot industries fanning the flames of this market rally. ...
Precipio ([[PRPO]] -6.6%) has begun to roll out Nirmidas Biotech's COVID-19 antibody tests following receipt of an Emergency Use Authorization from the FDA.The test, produced by Nirmidas, a biotech company based in Palo Alto, CA is the first U...
NEW HAVEN, Conn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that following receipt of an Emergency Use Authorization from the FDA by Nirmidas Biotech, Inc., the developer and manufacturer of...
Helius Medical Technologies (HSDT) -17%.Avinger (AVGR) -12%.Cango (CANG) -11%.OncoCyte (OCX) -10%.Obalon Therapeutics (OBLN) -10%.Dolphin Entertainment (DLPN) -9%.Surgalign Holdings (SRGA) -8% after pricing equity offering at $1.50.Vertex Energy (VTNR) -7%.Atossa Therapeutics (ATOS)...
News, Short Squeeze, Breakout and More Instantly...
NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Patholog...
NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that the company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) was convened and adjourned, without any business being conducted...
NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time. In order to e...